KAICO
Latest round
- Series A
Last raised
- Jan 2024
Total raised
- $7M
Investors
- 9
About KAICO
Founded in 2018 and based in Fukuoka, Japan, KAICO Ltd. produces proteins using the silkworm baculovirus expression method and commercially uses them for research reagents, diagnostic agents, and vaccines. In January 2024, KAICO Ltd.offers a range of products and services based on its core technology. The company provides services for the trial expression of customized proteins to support research and development efforts of its clients. The company also sells reagents derived from its recombinant protein production, which are used in various scientific research applications. Additionally, KAICO develops and commercializes proprietary supplements and vaccines for both animal and human use. The products are based on the recombinant proteins produced through the silkworm-baculovirus expression system. Additionally, the firm uses a genetically modified baculovirus to infect silkworms, which then produce recombinant proteins. The proteins are extracted and purified for various applications. The use of silkworms offers several advantages, including the ability to produce complex proteins that are difficult to express in other systems.
Who invested in KAICO
9 investors across 4 rounds
See all investors in KAICO
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about KAICO
Who invested in KAICO?
KAICO has 9 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has KAICO raised?
KAICO has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did KAICO last raise money?
KAICO's most recent round on record is a Series A, in Jan 2024.
What does KAICO do?
Founded in 2018 and based in Fukuoka, Japan, KAICO Ltd.
Where is KAICO headquartered?
KAICO is headquartered in Fukuoka-shi, Japan.
Which VCs invest in companies like KAICO?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at KAICO's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like KAICO? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.